Equilibrium dialysis, ultrafiltration, and ultracentrifugation were compared to determine their reliability and applicability in the study of binding of an anticonvulsant drug, valproic acid, by plasma proteins. We studied drug binding with pooled serum and with solutions of human serum albumin at physiological concentrations. We compared binding charactenstics such as number of binding sites, affinity constants, and percent of binding as measured by each method in the therapeutic range for valproic acid. Results by ultracentrifugation differed from those by equilibrium dialysis and ultrafiltration, which agreed reasonably well with each other. The plasma-protein binding of drugs continues to become more important for proper pharmacokinetic evaluations and in routine clinical monitoring of drugs (1-5). This is because, for many drugs, the therapeutic and (or) toxic response correlates better with the concentration of diffusible, unbound drug than with the total drug concentration (6). At present, the reliability of techniques for measuring the binding of drugs by plasma proteins is difficult to assess, there being no "standard" in measurements of drug-protein binding, unlike other routine biochemical tests. Equilibrium dialysis is often regarded as the "reference method" (7), especially for measurements of a drug that saturates plasma proteins even at therapeutic concentrations.
The availability of new ultraffitration and ultracentrifugation equipment has encouraged us to evaluate these methods and to compare results with those obtained by equilibrium dialysis. To our knowledge, there are no reports that directly compare the reliability of these methods in a single set of experiments. We therefore decided to use all three methods to investigate the protein binding of valproic acid (VPA, ndipropylacetic acid), a drug known to supersaturate the plasma proteins even at therapeutic concentrations (8).
Materials and Methods

Reagents
VPA solutions were prepared in phosphate buffer (67 mmol/L, pH 7.4, ionic strength 0.176) by isotopic dilution of a constant amount of '4C-labeled VPA (58 Ci/mol; Amersham International, Amersham, Bucks, U.K.) with increas- ing amounts of unlabeled drug. The purity of the [14CIVPA was assessed by using thin-layer chromatographic plates of silica gel (no. 5714; Merck, Darmstadt, F.R.G.) with the following solvent system: hexane/diethyl ether/acetic acid (80/20/1 by vol). It was found to exceed 98%.
VPA binding was studied with use of human serum albumin (HSA) (no. A-1887; Sigma Chemical Co., St Louis, MO) containing 40 mmol of free fatty acid (FFA, expressed as palmitic acid) per mole of HSA. HSA was dissolved in the phosphate buffer to give a concentration of 600 nol/L. Plasma lipoproterns, very-low (VLDL), low-(LDL), and high-density (HDL), were isolated by ultracentrifugation from pooled normolipidemic human serum as described by Glasson et al. (9) . We also used pooled human serum from healthy subjects. We detected trace amounts of protein in the supernates by the method of Lowry et al. (11) after ultracentrifugation (sensitivity: 2 pg/mL). VLDL, LDL, and HDL concentrations in serum corresponding to apolipoproteins B (VLDL + LDL) and A (LDL) were measured by radial immunodiffusion on plates (M. Partigen, Behringwerke, F.R.G.).
Binding techniques.
VPA binding to HSA and serum was measured by equilibrium dialysis, ultrafiltration, and ultracentrifugation. We investigated two ranges of VPA concentrations, one (4-14 000 tmol/L) to determine the binding parameters, the other (150-3000 nnol/L) to investigate the influence of the kind of technique used on the measurement of VPA binding. Each experiment was run in triplicate and the results were expressed as the mean ±SD.
For equilibrium dialysis, we used Teflon microcells (Dianorm#{174}; Diachema, Ruschlikon, Zurich, Switzerland) with two 200-giL chambers separated by a semipermeable membrane (Mr cutoff 12 000; Union Carbide, Chicago, IL). Samples were stirred constantly at 20 rotations per minute, at 37 #{176}C. We introduced VPA into the buffer compartment to check for the absence of binding to lipoproteins and to determine the parameters of VPA binding to serum and HSA. We added VPA to serum in a minimum volume of phosphate buffer to facilitate the comparison of percentage binding with those obtained by the other techniques. The ratio of this added volume to serum sample volume never exceeded 0.05, so that dilution of serum protein was negligible.
In preliminary experiments, we found that equilibrium was attained after 3 h of dialysis in all cases, so all samples were measured after that interval. No degradation of 4C-labeled VPA was found by thin-layer chromatographic measurement after completion of dialysis. In the dialysis of serum, the magnitude of the volume shift from the buffer to the protein compartment was negligible (<10%), so we did not correct for it. We measured the concentrations of VPA in both compartments after dialysis, accounting for at least 95% of the drug.
For ultrafiltration, we used the EMIT free level ifiter system (Syva Co., Palo Alto, CA), placing in the sample reservoir 1-mL portions of protein solutions supplemented with various concentrations of VPA. We obtained ultraffitrate containing free VPA by subjecting the system to lowspeed centrifugation (900 x g, 37#{176}C). HSA and serum samples were centrifuged for 5 and 10 mm, respectively. We then could collect a volume of ultraflltrate ranging between 10 and 15% of the initial sample volume. Analytical recovery of VPA in this system was also about 95%. For ultracentrifi.igation, we used polyallomer tubes (Beckman) containing 230 pL of the protein solutions, and we centrifuged them at 100000 x g for 6 h at 37 #{176}C, in a 42.2 Ti fixed-angle rotor (Beckman). The serum samples used were supplemented with VPA in the same way as for ultrafiltration. Free valproic acid in the supernate was measured as indicated in the following section. No degradation of ['4CIVPA was found by thin-layer chromatography after ultracentrifugation was completed. Analytical recovery of VPA in this system was 100%.
At the end of each kind of experiment, we measured the concentrations of either free or bound drug (or both) in an SL 3000 liquid-scintillation counter (Kontron SA, V#{233}lizy-Villacoublay, France).
In dialysis experiments, we counted the radioactivity of 100-jL portions from each compartment in "Ready-Solv MP" (Beckman) scintillation cocktail.
In ultrafiltration experiments,
we measured a 50-FL aliquot of the ultrafiltrate containing free VPA. The concentration of bound drug was calculated by subtracting the concentration of free drug from the total concentration introduced into the system.
In ultracentrifugation experiments, counting the radioactivity of 50 pL of the supernate allowed us to determine the concentration of free VPA. The concentration of the bound drug was the same as for ultrafiltration.
Calculations of percentage
VPA bound.
In equilibrium dialysis experiments, the percent of bound can be expressed as
where B is the total drug concentration in the protein compartmemt and A the free-drug concentration in the buffer compartment. In ultrafiltration and ultracentrifugation techniques, the percentage binding was determined as follows:
where F denotes the free-drug concentration determined in the ultrafiltration or the supernate and T is the total drug concentration introduced into the system. Statistical calculations. We compared the binding parameters as determined by each method with the other two by calculating Student's 95% confidence interval.
We compared the percent binding by using a two-way analysis of variance for balanced data. The confidence intervals based on the residual variance were computed for each pair of techniques (13). HSA binding parameters.
Results
Determination
Binding of VPA over the range of 4 to 14 000 moI/L at an HSA concentration of 600 mol/L was studied by equilibrium dialysis, ultraffitration, and ultracentrifugation techniques. In all cases the percentage binding decreased from approximately 98% to 10% as concentrations of VPA were increased. In Figure 1, Serum binding parameters. The range of VPA concentrations was the same as that previously used for HSA. For the three techniques, the percent of binding decreased from approximately 94% to 15% as the concentration of VPA increased. These binding curves are also shown in Figure 1 .
As with lISA, two classes of sites can be determined. Table 1 lists the concentrations of the binding sites for each class and their corresponding affinity constants. The statistical calculations were performed in the same manner as for HSA. For the first class of binding sites, the afilnity constant as determined by equilibrium dialysis was higher than those determined by the other two techniques but was significantly different only from that obtained by ultracentrifugation. For the second class, the affinity constant measured by equilibrium dialysis was significantly higher (p <0.05) than that determined by ultracentrifugation. However, the FFA concentration in serum was 520 molJL before dialysis and 450 moLIL after dialysis was completed.
VPA binding in serum. The percent of binding in serum was measured by the three techniques. Samples were supplemented with VPA over a range of 150-3000 mol/L. The results are listed in Table 2 . A significant overall difference was found among the three techniques (p <0.001). The confidence intervals showed a significant difference for each pair of techniques (p <0.05). However, it is clear from these results that the ultrafiltration values are much closer to those for equilibrium dialysis than to those obtained by ultracentrifugation.
The results show that the maximum differences in percentages were 8.4% for equilibrium dialysis vs ultrafiltration, 20% for equilibrium dialysis vs ultracentrifugation, and 13% for ultrafiltration vs ultracentrifugation.
A comparison of the percent of binding obtained by the three methods was also made from another set of experiments. In these experiments, VPA in the range 150-3000 pmol/L was introduced into the buffer compartment and was equilibrated with serum. When equilibrium was achieved, the protein compartment was emptied; aliquots of these serum samples were used, as usual, for liquid scintillation counting to determine the bound VPA. The remainder was used to measure the binding percentages by the other two techniques. Once again, a significant difference (p <0.001) was found among the three techniques and between each pair of methods (p <0.05) (Table 3) . Moreover, the results show differences of 2.5% for equilibrium dialysis vs ultrafiltration, 7% for equilibrium dialysis vs ultracentriftigation, and 8% for ultrafiltration vs ultracentriftigation.
Each result is the mean (± SD) of three determinations. After completion of dialysis of pooled serum supplemented with VPA, the protein compartments containing free plus bound VPA were collected. Then an aliquot was subjected to ultrafiltration and ultracentrifugation. Each method differed significantly from the other two (p <0.05).
Discussion
The characteristics of the two classesof VPA binding sites in both serum and HSA solutions as determined by equilibrium dialysis-which is often regarded as the reference method-are in good agreement with those found by Unen et al. tration, and ultracentrifugation do not show any significant differences. However, some significant differences appeared in the second class of binding sites when we compared the values for n and K obtained by each method. When one compares the products n1K1 and n2K2, which reflect the binding capacities of the two classes, it can be seen that the contribution of the second class of sites is about one hundredth that of the first. Therefore, the discrepancies in the binding constants of the second class between the three methods should not affect the interpretation of the overall binding characteristics of the drug. For serum, the affinity constant of the first class (K1) determined by ultracentrifugation is significantly lower than that obtained by equilibrium dialysis. In addition, the K1 obtained with the ultrafiltration method is less than that obtained by equilibrium dialysis, although the difference is not significant. The observed decrease in K1 when determined by equilibrium dialysis, ultrafiltration, and ultracentrifligation, respectively, may be partly due to the differing concentrations of FFA in the serum at the end of each experiment. In equilibrium dialysis, a part of the FFA initially present in the protein compartment is observed to diffuse into the buffer compartment, sothat the final FFA concentration shows a decrease. Since no such dilution effect occurs in either ultrafiltration or ultracentrifugation, the FFA concentrations remain constant during these two experimental procedures. This phenomenon may be of importance, because it has previously been shown that FFA competitively inhibits the binding of VPA to HSA (12). This is also likely to occur with other unknown endogenous compounds that may interfere with VPA binding.
In our experiments with HSA, some significant differences were found in serum when we compared the parameters of the second class of sites measured with the three techniques. There could be additional reasons for differences observed in the results between equilibrium dialysis and ultracentrifugation. The discrepancies could be partly due to the VPA binding to lipoproteins, namely VLDL and LDL, which can remain in the supernate and cause a spurious increase in the free-drug concentration. This may not occur for VPA because this drug is not bound to lipoproteins. It is commonly believed that the binding equilibrium is altered during ultracentrifugation. However, according to Gilbert and Jenkins (14), equilibrium is not significantly affected if the drug-protein complex shifts with the same speed as that of the protein alone. This may have happened in our situation, because the relative molecular masses of lISA and of the complex VPA-HSA are, respectively, 66000 and 66 163. A free VPA concentration gradient developing in the supernate during ultracentrifugation and causing sedimentation is unlikely, because it has been previously shown (7, 15 ) that this phenomenon is negligible for low-Me drugs such as VPA. Rather, drugs of low molecular mass were shown to diffuse back from the bottom to the top of the tubes, mainly because of thermal agitation of the molecules (7) . Such a back diffusion of VPA may have occurred in our experiments, causing an altered equilibrium and subsequently an overestimation of the free-drug concentration.
Unfortunately, these possibilities could not be investigated because of the inadequate volume (150 1L) and height (9 mm) of the supernate.
To evaluate the validity of the three methods for clinical purposes, we determined the percent of binding in serum supplemented with VPA (Table 2 ). Our results show that, throughout the range studied, there was a highly significant difference between equilibrium dialysis and ultrafiltration. It may be that a dilution effect, due to the diffusion of the free drug from the protein compartment to the buffer compartment during the dialysis, causes a disruption of the equilibrium, thus accounting for this difference. Furthermore, the dilution of FFA may partly explain the higher percent of binding found in dialysis. At saturating concentrations of drugs the differences are much greater than at non-saturating concentrations, a fact well depicted by our results, because the difference can reach 7% for high VPA concentrations, even within the therapeutic range (200-900 Mmol/L), while it is only 4% for low VPA concentrations. Ultracentrifugation yields a much lower percent of binding than the other two methods, probably for the reasons already discussed.
To circumvent the dilution effect of equilibrium dialysis for the comparison of the three techniques, ultrafiltration and ultracentrifugation were performed sequentially on serum samples that had already been dialyzed. Although a significant difference was observed ( Table 3) between ultrafiltration and equilibrium dialysis (lower values obtained with the latter method at higher concentrations), the two series of values were reasonably close for clinical purposes. The maximum difference did not exceed 1.1% within the therapeutic range previously defined, and 2.9% over the whole range studied. Previous reports (16, 17) have shown that there is no disturbance of equilibrium during ultrafiltration partition. In ideal situations, when the binding parameters-that is, the number of sites and the affinity constants-remain unchanged irrespective of the protein concentration, the concentration of free drug measured by ultrafiltration partition is unaltered regardless of the concentration of retained binding protein. However, when one is dealing with a drug such as VPA, the binding parameters may vary with the protein concentration (12). In our experiments, free VPA concentrations remained constant even when the volume of ultrafiltrate ranged from 10 to 60% of the HSA solutions or serum samples ultrafiltered. Thus, despite the high variations in retained protein concentrations in the upper reservoir, no disturbance of the protein binding equilibrium was apparent.
Currently, there is no "standard" method for protein binding measurements. Most of the investigations have been performed by using equilibrium dialysis, mainly because this method offers the advantage that free and bound amounts of the drug are not separated and, therefore, equilibrium of binding will not be affected. This reason chiefly accounts for the considerable amount of data now available with this technique. Therefore, equilibrium dialysis may still be regarded as the reference technique to use in investigating the binding characteristics of a new drug to serum or to a particular protein such as the determination of n and K. One should also refer to this technique to validate other techniques such as ultrafiltration and ultracentrifugation.
However, this technique is limited by several drawbacks, such as a dilution effect of the drug and the endogenous compounds in the buffer compartment and the longer time necessary to determine the binding characteristics. Obviously, this may not be a suitable procedure for drugs prone to hydrolysis in serum. In light of those limitations, it seems more judicious to choose either ultrafiltration or ultracentrifugation to evaluate the binding percentage of a drug for clinical purposes. In our study, ultrafiltration gave results closer to those obtained with equilibrium dialysis than did ultracentrifugation.
Further, ultracentrifugation requires costly equipment, and some physical phenomena-such as sedimentation, back diffusion, viscosity, and binding to plasma lipoproteins in the supernatant fluid-can cause errors in the estimation of the free-drug concentration.
Ultrafiltration may pose problems if there is significant nonspecific adsorption onto the membrane. In view of these potential problems, a careful comparative study should always be made before one of these two techniques is chosen for use in routine clinical practice.
